MR-documented remission of pituitary stalk infiltration in patients with Langerhans cell histiocytosis following treatment with 2-chlorodeoxyadenosine

Česká verzia

Authors: J. Vaníček ¹; Z. Adam ²; K. Balšíková ³; M. Krejčí ²; L. Pour ²; P. Szturz ²; L. Zahradová ²; R. Hájek ²; R. Koukalová ⁴; Z. Řehák ⁴; Z. Král ²; J. Mayer ²
Authors place of work: Klinika zobrazovacích metod Lékařské fakulty MU a FN u sv. Anny v Brně, zastupující přednosta as. MUDr. Jiří Vaníček, Ph. D. ¹; Interní hematoonkologická klinika Lékařské fakulty MU a FN Brno, pracoviště Bohunice, přednosta prof. MUDr. Jiří Mayer, CSc. ²; II. interní klinika Lékařské fakulty MU a FN u sv. Anny v Brně, přednosta prof. MUDr. Miroslav Souček, CSc. ³; Oddělení PET CT Masarykova onkologického ústavu v Brně, přednosta prim. MUDr. Karol Bolčák, Ph. D. ⁴
Published in the journal: Vnitř Lék 2011; 57(10): 871-875
Category: Case Reports

Summary

In adult patients, Langerhans cell histiocytosis (LCH) manifests most frequently with one or more osteolytic lesions or, alternatively, with pulmonary involvement with nodules and cysts or with skin lesions. Infiltration of the central nervous system is a rather rare sign of LCH. The LCH cells have an unexplained affinity to hypothalamus and to pituitary stalk and, consequently, central diabetes insipidus is the most frequent clinical sign of brain involvement in LCH. We describe treatment of 2 adult patients with LCH in whom central diabetes insipidus was the first sign of LCH and MR confirmed pituitary stalk infiltration. The first man was diagnosed with diabetes insipidus and pituitary stalk infiltration at 33 years of age. LCH was confirmed 2 years later by histology of verrucous lesions on the skin of perianal area. The disease affected the skin and CNS. The patient was treated with 2-chlorodeoxyadenosine (5 mg/m² s.c. for 5 consecutive days of a 28-day cycle). No pituitary infiltration was evident on an MR image after the 4th cycle. Residual perianal infiltration was irradiated. The patient has been in complete remission for 44 months following treatment completion, although vasopressin and testosterone substitution is required. The second man was also diagnosed with diabetes insipidus and pituitary stalk infiltration at 33 years of age. Pulmonary involvement was identified with high resolution CT (HRCT) and high CD1a and S-100 positive elements with bronchoalveolar lavage. This patient further had external auditory canal infiltrations causing chronic discharge from the ears. The patient was treated with 2-chlorodeoxyadenosine as above. A follow up MR after the 4th cycle showed reduction in the infiltration diameter from 5.5 to 3.0 mm. Therefore, 2-chlorodeoxyadenosine 5 mg/m² s.c. was combined with dexamethasone 20 mg p.o. during the 5th and 6th cycle. The MR image after treatment completion showed remission of the pituitary stalk infiltrate. External auditory canal infiltration diminished as did the nodules in pulmonary parenchyma. Nevertheless, vasopressin substitution is still required. The patient has been in complete remission for 8 months from the completion of the treatment. Pituitary stalk infiltration disappeared after the treatment with 2-chlorodeoxyadenosine in 2 patients; after 4 cycles in the first and after 6 cycles (with an addition of dexamethasone during the last 2 cycles) in the second.

Key words:
Langerhans cell histiocytosis – diabetes insipidus centralis – pituitary infiltration – 2-chlorodeoxyadenosine – cladribine – otitis externa – PET-CT

Zdroje

1. Ščudla V, Roček V, Dušek B et al. Multifokální eozinofilní granulom v dospělosti. Vnitř Lék 1987; 33: 1078–1086.

2. Dufka A, Šálek T. Recidivující synkopa jako vedoucí symptom u parciálního centrálního diabetu insipidu. Interní med pro praxi 2007; 4: 195–197.

3. Votava F. Diferenciální diagnostika polyurie a polydipsie. Čes Slov Pediat 2001; 56: 655–659.

4. Loh JA, Verbalis JG. Disorders of water and salt metabolism associated with pituitary disease. Endocrinol Metab Clin North Am 2008; 37: 213–234.

5. Müssig K, Beschorner R. Rare differential diagnosis of diabetes insipidus. Dtsch Med Wochenschr 2008; 133: 2159–2160.

6. Aricò M, Girschikofsky M, Généreau T et al. Langerhans cell histiocytosis in adults. Report from the International Registry of the Histiocyte Society. Eur J Cancer 2003; 39: 2341–2348.

7. Fichter J, Doberauer C, Seegenschmiedt H. Langerhans cell histiocytosis in adults: An interdisciplinary challenge. Dtsch Arztebl 2007; 104: 2347–2353.

8. Allen CE, McClain KL. Langerhans cell histiocytosis: a review of past, current and future therapies. Drugs Today 2007; 43: 627–643.

9. Carrera CJ, Terai C, Lotz M et al. Potent toxicity of 2-chlorodeoxyadenosine toward human monocytes in vitro and in vivo. A novel approach to immunosupressive therapy. J Clin Invest 1996; 86: 1480–1488.

10. Liliemark J. The clinical pharmacokinetics of cladribine. Clin Pharmacokinet 1997; 32: 120–131.

11. Bryson MH, Sorkin EM. Cladribine: A review of its pharmacodynamics and pharmacokinetics properties and therapeutic potential in haematologic malignancies. Drugs 1993; 46: 872–891.

12. Liliemark J, Albertoni F, Hasan M et al. On the bioavailability of oral and subcutaneous 2-chlorodeoxadenosine in human. Alternative routes of administration. J Clin Oncol 1992; 10: 1514–1518.

13. Robak T, Lech-Maranda E, Korycka A et al. Purine nukleoside analogs as immunosupressive and antineoplastic agents: Mechanismus of action and clinical activity. Curr Med Chem 2006; 13: 3165–3189.

14. McClain KL. Drug therapy for the treatment of Langerhans cell histiocytosis. Expert Opin Pharmacother 2005; 6: 2435–2441.

15. Saven A, Figueroa ML, Piro LD et al. 2-Chlorodeoxyadenosine to treat refractory histiocytosis X. N Engl J Med 1993; 329: 734–735.

16. Weitzman S, Wayne AS, Arceci R et al. Nucleoside analogues in the therapy of Langerhans cell histiocytosis: a survey of members of the histiocyte society and review of the literature. Med Pediatr Oncol 1999; 33: 476–481.

17. Imamura T, Sato T, Shiota Y et al. Outcome of pediatric patients with Langerhans cell histiocytosis treated with 2 chlorodeoxyadenosine: a nationwide survey in Japan. Int J Hematol 2010; 91: 646–651.

18. Weitzman S, Braier J, Donadieu J et al. 2‘-Chlorodeoxyadenosine (2-CdA) as salvage therapy for Langerhans cell histiocytosis (LCH). Results of the LCH-S-98 protocol of the Histiocyte Society. Pediatr Blood Cancer 2009; 53: 1271–1276.

19. Pardanani A, Phyliky RL, Li CY et al. 2-Chlorodeoxyadenosine therapy for disseminated Langerhans cell histiocytosis. Mayo Clin Proc 2003; 78: 301–306.

20. Watts J, Files B. Langerhans cell histiocytosis: central nervous system involvement treated successfully with 2-chlorodeoxyadenosine. Pediatr Hematol Oncol 2001; 18: 199–204.

21. Dhall G, Finlay JL, Dunkel IJ et al. Analysis of outcome for patients with mass lesions of the central nervous system due to Langerhans cell histiocytosis treated with 2-chlorodeoxyadenosine. Pediatr Blood Cancer 2008; 50: 72–79.

22. Stine KC, Saylors RL, Saccente S et al. Eff icacy of continuous infusion 2-CDA (cladribine) in pediatric patients with Langerhans cell histiocytosis. Pediatr Blood Cancer 2004; 43: 81–84.

23. Ottaviano F, Finlay JL. Diabetes insipidus and Langerhans cell histiocytosis: a case report of reversibility with 2-chlorodeoxyadenosine. J Pediatr Hematol Oncol 2003; 25: 575–577.

24. Mottl H, Ganevová M, Radvanská J et al. Treatment results of Langerhans cell histiocytosis with LSH II protocol. Čas Lék Čes 2005; 144: 753–755.

25. Mottl H, Starý J, Chánová M et al. Treatment of recurrent Langerhans cell histiocytosis in children with 2-chlorodeoxyadenosine. Leuk Lymphoma 2006; 47: 1881–1884.